Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 1.00 |
| ▸ | POLB | P06746 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | THRB | P10828 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 9/20 | 0.74 |
| ▸ | BLM | P54132 | 3/20 | 0.74 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721359 | 0.89 | MAPT (0.81) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6721369 | 0.86 | MAPT (0.82) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6721418 | 0.86 | MAPT (0.79) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6721389 | 0.85 | MAPT (1.00) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6721415 | 0.84 | MAPT (1.00) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6721420 | 0.79 | MAPT (0.80) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12127306 | 0.79 | MAPT (0.69) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14581052 | 0.78 | MAPT (0.65) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6721437 | 0.77 | MAPT (0.79) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL880463 | 0.75 | GAA (0.74) | MAPTPOLBMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998974-B2 | Fused heterocyclic compounds and their use as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998974-B2 | Fused heterocyclic compounds and their use as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SITRIS PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143376-A1 | Fused Heterocyclic Compounds and Their Use as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | MAPT 215/4885POLB 1489/4885MEN1 4100/4885 |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | MAPT 1946/4885POLB 201/4885MEN1 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.